Hong Kong Insurance Stock News

Analyst downgrade puts Wharf (Holdings) (SEHK:4) back in focus Citi’s latest report on Hong Kong real estate stocks, including a Sell call on Wharf (Holdings) (SEHK:4), has drawn attention to short selling activity and the stock’s discount to net asset value. See our latest analysis for Wharf (Holdings). Wharf (Holdings)’ share price has been relatively steady around HK$23.02, with a 7 day share price return of 4.07% and a 90 day share price return of 6.08%. Its 1 year total shareholder...

AsiaInfo Technologies announced that long-serving executive director and CEO Gao Nianshu retired on 31 December 2025, with Chief Technology Officer Dr. Ye Ouyang appointed as the new CEO from 1 January 2026 and stepping into broader leadership responsibilities. Dr. Ye’s deep background in network intelligence, AI, and large-scale R&D management, together with extensive industry and academic recognition, brings a technology-focused leadership profile that could influence how AsiaInfo...

BOC Hong Kong (Holdings) Limited recently renewed its Services and Relationship Agreement with controlling shareholder BOC Group, extending various general, investment, referral and inter-bank connected transactions from 1 January 2026 to 31 December 2028 under new caps that now require independent shareholders’ approval. The move formalises one of the bank’s core operating relationships under Hong Kong listing rules, with an Independent Board Committee and external adviser Gram Capital...

BYD Company Limited recently reported unaudited figures showing December 2025 sales of 420,398 units and production of 419,804 units, both lower than the same month a year earlier, while full-year 2025 sales and production increased compared with 2024. This mix of softer year-end monthly volumes alongside higher annual totals highlights a potential shift in demand momentum as the company enters 2026. We will now examine how BYD’s weaker December volumes but higher full-year totals shape the...

As global markets kick off 2026, investors are witnessing a rally in U.S. stocks despite signs of a weakening labor market and persistent geopolitical tensions, with small-cap and value shares leading the charge. In this climate of economic uncertainty and fluctuating indices, identifying undervalued stocks becomes crucial for value investors seeking to capitalize on potential opportunities amidst these shifting dynamics.

Key Insights The considerable ownership by public companies in BYD Electronic (International) indicates that they...

Yadea Group Holdings (SEHK:1585) has issued new earnings guidance, telling investors it expects net profit of at least CN¥2.9b for 2025, compared with CN¥1.27b in 2024. See our latest analysis for Yadea Group Holdings. The earnings guidance comes as Yadea’s share price performance has been relatively mixed, with a 9.17% 7-day share price return and a 5.20% year-to-date share price return. The 1-year total shareholder return is 6.87%, while the 3- and 5-year total shareholder returns remain...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...

As 2026 begins, Asian markets are capturing investor attention with strong performances, particularly in China and Japan, where indices have shown notable gains amid optimism about the domestic tech sector and consumer spending. In this environment of growth and potential policy shifts, identifying stocks that are estimated to be trading below their intrinsic value can present compelling opportunities for investors seeking to capitalize on undervalued assets in a thriving market.

Key Insights Significant control over Ruifeng Power Group by private companies implies that the general public has more...

Key Insights Significant insider control over T.S. Lines implies vested interests in company growth 74% of the business...

China Ruyi Holdings Limited ( HKG:136 ) shareholders might be concerned after seeing the share price drop 15% in the...

With its stock down 11% over the past week, it is easy to disregard Numans Health Food Holdings (HKG:2530). Given that...

Suzhou Basecare Medical Corporation Limited's ( HKG:2170 ) price-to-sales (or "P/S") ratio of 1.9x might make it look...

Kingsoft Corporation announced that on 30 December 2025 it entered a six-year lease with Xiaomi affiliate Beijing Duokan and renewed a three-year framework agreement with Xiaomi covering mutual services, game co-operation and product supply through 2028. The renewed Xiaomi agreements deepen Kingsoft’s reliance on a related-party ecosystem while formalizing recurring service, gaming and ancillary transactions under Hong Kong connected transaction rules. We’ll now examine how this extended...

Perennial Energy Holdings Limited's ( HKG:2798 ) price-to-earnings (or "P/E") ratio of 9.6x might make it look like a...

There wouldn't be many who think Evergreen Products Group Limited's ( HKG:1962 ) price-to-earnings (or "P/E") ratio of...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yidu Tech Inc. ( HKG:2158 ) shareholders would be excited to see that the share price has had a great month, posting a...

Most readers would already be aware that Shanghai Electric Group's (HKG:2727) stock increased significantly by 9.2...

It's not a stretch to say that Starlite Holdings Limited's ( HKG:403 ) price-to-sales (or "P/S") ratio of 0.1x right...

As we enter 2026, Asian markets are capturing global attention with their robust performance, driven by optimism in the tech sector and a resurgence in consumer spending. Amidst this momentum, investors are increasingly looking for value stocks—those trading below their estimated worth—that could offer potential opportunities within this thriving economic landscape.

As we enter January 2026, Asian markets are experiencing a notable upswing, with equities advancing and indices reaching new heights amid global optimism. In this context, penny stocks—typically representing smaller or newer companies—continue to capture investor interest due to their potential for growth at lower price points. While the term "penny stocks" may seem outdated, these investments can still offer value when supported by strong financials and solid fundamentals, presenting an...

EQRx, based in Cambridge, USA, previously reported new clinical trial data for its lung cancer candidate sugemalimab, a monoclonal antibody developed in collaboration with CStone Pharmaceuticals, with plans to present the findings at the World Conference on Lung Cancer 2021. The therapy’s design to mirror a naturally occurring antibody, potentially lowering immunogenicity and toxicities, highlights CStone’s exposure to differentiated immuno-oncology innovation through this partnership. We’ll...